Last reviewed · How we verify

Lamivudine Oral Solution — Competitive Intelligence Brief

Lamivudine Oral Solution (Lamivudine Oral Solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside reverse transcriptase inhibitor (NRTI). Area: Infectious Disease.

marketed Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase; Hepatitis B virus polymerase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Lamivudine Oral Solution (Lamivudine Oral Solution) — ANRS, Emerging Infectious Diseases. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV reverse transcriptase, preventing viral replication by inhibiting the conversion of viral RNA to DNA.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Lamivudine Oral Solution TARGET Lamivudine Oral Solution ANRS, Emerging Infectious Diseases marketed Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase; Hepatitis B virus polymerase
Epivir (3TC) Epivir (3TC) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) phase 3 Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase; Hepatitis B virus polymerase
entecavir, lamivudine entecavir, lamivudine Asan Medical Center marketed Nucleoside reverse transcriptase inhibitor (NRTI) Hepatitis B virus reverse transcriptase
ZIAGEN® ZIAGEN® ViiV Healthcare marketed Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase
Lamivudine (LAM) Lamivudine (LAM) Hoffmann-La Roche marketed Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase; Hepatitis B virus reverse transcriptase
3TC 3TC Avexa marketed Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase; hepatitis B polymerase
lamivudine or entecavir lamivudine or entecavir Sun Yat-sen University marketed Nucleoside reverse transcriptase inhibitor (NRTI) / Nucleotide reverse transcriptase inhibitor (NtRTI) Hepatitis B virus reverse transcriptase; HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside reverse transcriptase inhibitor (NRTI) class)

  1. French National Agency for Research on AIDS and Viral Hepatitis · 3 drugs in this class
  2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
  3. ViiV Healthcare · 2 drugs in this class
  4. Nanfang Hospital, Southern Medical University · 2 drugs in this class
  5. Asan Medical Center · 1 drug in this class
  6. Dong-A ST Co., Ltd. · 1 drug in this class
  7. Bristol-Myers Squibb · 1 drug in this class
  8. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
  9. Fu-Sheng Wang · 1 drug in this class
  10. Avexa · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lamivudine Oral Solution — Competitive Intelligence Brief. https://druglandscape.com/ci/lamivudine-oral-solution. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: